October 16, 2014
The major current issues include:
• Which TKI should be the initial preferred agent: the first-generation TKI imatinib, or the approved second-generation TKIs dasatinib and nilotinib, which appear to be more active in the short term, but so far have not had a long-term survival advantage over imatinib?
• Should physicians change TKIs early (3 months) on the basis of short-term disease response?
• What types of patients should be referred for discontinuation trials